the full story...thanks IVRT...
DNAPrint genomics, Inc. Eligible for Quotation on NASDAQ OTC Bulletin Board
SARASOTA, Fla.--(BUSINESS WIRE)--Feb. 22, 2001--DNAPrint genomics, Inc. (OTCBB:DNAP) announced today that the Company is now eligible for quotation on the NASDAQ OTC Bulletin Board.
DNAPrint genomics, Inc. is developing complex genetic analytics and information resources for next generations personalized medicine. The company's products will constitute a line of genomics based diagnostics kits and informational/analytical resources that will enable the use of individual genetic profiles to match patients with drugs and classify patient proclivities for complex disease.
Variable drug efficacy and/or drug-related adverse events cost the health care system billions of dollars each year. As predictive, prophylactic tools (to help prevent disease rather than just report it), genomics-based diagnostic products could potentially open and expand drug markets from the sick to the healthy.
"Genomics based diagnostic products such as those we are developing could be inherently more valuable and profitable than traditional diagnostic products," said DNAPrint Chief Executive Officer, Dr. Tony Frudakis. "Our progress to date building an infrastructure for the development of these types of products has been encouraging. With this new listing, we fulfill another company objective and come one step closer to our long-term goal of becoming the premier genomics-based diagnostics company in the world."
DNAPrint genomics Inc. was founded by a team of scientists with research and commercial experience in high-level mathematical modeling, programming and molecular genetics. The Company is traded under the ticker symbol: DNAP. For more information about the company, please visit www.dnaprint.com
All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
CONTACT: DNAPrint genomics, Inc., Sarasota, Fla.
For Scientific inquiries:
Dr. Tony Frudakis, 941/351-4543
or
Other inquiries:
Richard Craig Hall, 941/341-0136
good fortune...
pops
News 
Market Data 
Discover 
AI
